Treatment of acne with spironolactone: a retrospective review of 395 adult patients at Mayo Clinic, 2007-2017

被引：20

作者：

Roberts, E. E. ^{[1
]}

Nowsheen, S. ^{[2
]}

Davis, M. D. P. ^{[1
]}

McEvoy, M. T. ^{[1
]}

Newman, C. C. ^{[1
]}

Valinotti, J. C. Sartori ^{[1
]}

Sciallis, G. F. ^{[1
]}

Torgerson, R. R. ^{[1
]}

Wetter, D. A. ^{[1
]}

机构：

[1] Mayo Clin, Dept Dermatol, Rochester, MN 55905 USA

[2] Mayo Clin, Med Scientist Training Program, Coll Med & Sci, Rochester, MN USA

来源：

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY | 2020年 / 34卷 / 09期

关键词：

ORAL SPIRONOLACTONE; VULGARIS; WOMEN; ANTIBIOTICS;

D O I：

10.1111/jdv.16302

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Background Few large studies have assessed spironolactone treatment of adult female acne. Objectives To explore the role of spironolactone in the treatment of adult female acne. Methods We performed a retrospective case series assessing the efficacy of spironolactone treatment of a cohort of women evaluated at Mayo Clinic in Rochester, Minnesota, from 2007 through 2017. Results In total, 395 patients (median age, 32 years) received a median spironolactone dose of 100 mg daily. Approximately two-thirds of patients (66.1%) had a complete response; 85.1% had a complete response or a partial response greater than 50%. Median times to initial response and maximum response were 3 and 5 months. Efficacy was observed across all severity subtypes of acne, including those with papulopustular and nodulocystic acne. Patients received long-term treatment with spironolactone (median duration, 13 months) and had few adverse effects. Conclusions Spironolactone is a safe and effective treatment of acne for women.

引用

页码：2106 / 2110

页数：5

共 19 条

[1] Approaches to limit systemic antibiotic use in acne: Systemic alternatives, emerging topical therapies, dietary modification, and laser and light-based treatments [J].